Defunct Company
Total Trials
11
As Lead Sponsor
9
As Collaborator
2
Total Enrollment
741
NCT00316537
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 31, 2006
Completion: Jul 31, 2007
NCT00414622
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
Phase: Phase 2
Start: Nov 30, 2006
Completion: Apr 30, 2007
NCT00419445
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
Start: Feb 28, 2007
Completion: Jan 31, 2008
NCT00414206
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
Start: Mar 31, 2007
Completion: Sep 30, 2009
NCT00621010
Safety Study of CTS21166 to Treat Alzheimer Disease
Phase: Phase 1
Start: Jun 30, 2007
Completion: Feb 29, 2008
NCT00536692
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
Start: Sep 30, 2007
Completion: Apr 30, 2008
NCT00607750
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
Start: May 31, 2008
Completion: May 31, 2010
NCT00783068
Anti-inflammatory Effects of GTS-21 After LPS
Phase: N/A
Role: Collaborator
Start: Aug 31, 2008
Completion: Aug 31, 2010
NCT02331433
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
Start: Dec 31, 2014
Completion: Dec 31, 2015
NCT02724917
Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
Start: Apr 30, 2016
Completion: Dec 31, 2016
NCT04595669
Personalised Advice for the Prevention of Metabolic Syndrome
Start: Sep 4, 2017
Completion: Dec 21, 2017